Note | |
| |
Entity | Thyroid cancer |
Disease | NIS-mediated uptake of radionuclides has long been exploited in diagnostic scintigraphic imaging (123I, 131I, 99mTcO4-) and radiotherapy (131I) of thyroid carcinoma of follicular cell origin. Compared to other cancers, the prevalence of thyroid cancer is relatively low and its prognosis after surgery and radioiodine therapy is mostly favorable. However, radioiodine uptake is frequently decreased in differentiated thyroid carcinoma (papillary and follicular) and is completely absent in 20% of differentiated carcinomas and most anaplastic thyroid carcinomas. Furthermore, the recurrence rate of thyroid cancer is high (10-30% for papillary thyroid carcinoma) and only one third of patients with distant metastases respond to 131I therapy with complete remission. NIS expression in thyroid cancer is controversial with reports of under-expression as well as over-expression (Arturi et al., 1998; Saito et al., 1998; Venkataraman et al., 1999; Lazar et al., 1999; Castro et al., 2001; Dohan et al., 2001; Ward et al., 2003; Trouttet-Masson et al., 2004). Low NIS expression identifies aggressive thyroid tumors and correlates with reduced radioiodine uptake and tumor dedifferentiation. Loss of NIS expression may be associated with hypermethylation of the NIS gene promoter, or may be secondary to reduced expression of nuclear transcription factors. When over-expressed, NIS is mostly intracellular suggesting defective targeting of the protein to the plasma membrane in these cases. Hypofunctioning thyroid tumors express low levels of non-glycosylated NIS suggesting that protein maturation may also be impaired. Several pharmacological approaches are being tested for their ability to promote cellular re-differentiation, increase endogenous NIS expression and restore iodide transport in thyroid carcinoma cell lines and in patients. Agents include retinoic acid, demethylating agents, histone deacetylase inhibitors and reverse transcriptase inhibitors (Schmutzler et al., 1997; Venkataraman et al., 1999; Zarnegar et al., 2002; Fortunati et al., 2004; Landriscina et al., 2005). The effectiveness of these agents, however, is variable and their clinical utility has yet to be proven. |
Oncogenesis | Although no somatic NIS mutations have been identified in thyroid carcinoma, alterations in other genes or gene products may be associated with NIS impairment. BRAF: Papillary thyroid carcinomas (PTC) harboring the BRAF V600E mutation have reduced NIS expression and impaired targeting to the plasma membrane, which correlates with reduced radioiodine uptake and high risk of recurrence (Riesco-Eizagirre et al., 2006). BRAF V600E-positive PTC also have reduced expression of other thyroid-specific genes such as thyroperoxidase and thyroglobulin, suggesting that impaired NIS expression may be part of an early dedifferentiation process present at the molecular level in BRAF V600E-mutated PTC (Durante et al., 2007; Romei et al., 2008). RET/PTC: Expression of RET/PTC rearrangements reduces radioiodide uptake and NIS expression in thyroid cells in vitro and transgenic mice (Cho et al., 1999; Knauf et al., 2003). No change in NIS expression, however, was detected in papillary thyroid carcinoma with RET/PTC rearrangements (Romei et al., 2008). PTTG: Differentiated thyroid cancer over-expresses pituitary tumor transforming gene (PTTG), a proto-oncogene involved in the control of sister chromatid separation. PTTG overexpression correlates with reduced radioiodine uptake and is a prognostic factor for persistent disease (Saez et al., 2006). PTTG downregulates NIS expression and I- uptake in vitro, possibly by repressing the binding of transcriptional regulators to the hNUE upstream enhancer (Boelaert et al., 2007). |
| |
| |
Entity | Breast cancer |
Disease | NIS is up-regulated in breast cancer and attention has recently focused on the potential application of radioiodine in the diagnosis and therapy of breast cancer. Several studies have detected NIS immunohistochemically in 30-90% of primary and metastatic breast carcinomas, with variable degrees of intracellular and plasma membrane staining (Tazebay et al, 2000; Wapnir et al, 2003; Wapnir et al., 2004; Beyer et al., 2008; Renier et al., 2009). Estimates of NIS expression in breast cancer, however, may be overestimated due to non-specific binding of some anti-NIS antibodies resulting in a diffuse intracellular staining. One study failed to detect significant NIS immunostaining in 30 cases of primary breast cancer (Peyrottes et al., 2009). In vivo scintigraphic imaging detected 123I or 99mTcO4 uptake in up to 25% of NIS-expressing breast tumors, suggesting that the expression of functional NIS in breast cancer is low (Moon et al., 2001; Wapnir et al., 2004). Current research is aimed at identifying strategies that increase the expression and membrane targeting of NIS in breast cancer, in order to improve the efficiency of NIS-mediated radionuclide uptake. |
| |
| |
Entity | Cholangiocarcinoma (CCA) |
Disease | NIS is up-regulated in CCA and is localized to the plasma membrane and/or cytoplasm of bile duct epithelial cholangiocytes. In the diethylnitrosamine rat model of liver cancer, NIS is expressed at the preneoplastic stages of liver carcinogenesis and enables tumor suppression after 131I radiotherapy (Liu et al., 2007). Radioiodide therapy may therefore represent a novel strategy for the treatment of CCA. |
| |
| |
Entity | Gastric cancer |
Disease | NIS expression, normally present in the gastric mucosa, is markedly decreased or absent in gastric cancer (Altorjay et al., 2007) and distinguishes malignant from benign gastric lesions (Farnedi et al., 2009). |
| |
| |
Entity | Various carcinomas |
Note | Targeted NIS gene therapy is being evaluated as a potential diagnostic and therapeutic option for various cancers, enabling tumor cells to accumulate NIS-transported radionuclides. Preclinical studies demonstrate NIS expression, radioiodide uptake and tumor cell death in vitro and in vivo following targeted adenoviral NIS gene transfer to tumor cells. A phase I clinical trial is ongoing to study the efficacy and safety of NIS gene therapy and radioactive iodine for the treatment of prostate cancer (NCT00788307, www.clinicaltrials.gov). |
Disease | Carcinomas of the prostate, cervix, breast, head and neck, lung, liver, thyroid, colon, ovaries and pancreas; myeloma; glioma. |
| |
| |
Entity | Thyroid adenoma |
Disease | Benign nonfunctioning thyroid adenomas are characterized by reduced radioiodine uptake due to reduced NIS expression or defective targeting of NIS to the plasma membrane (Tonacchera et al., 2002). A loss-of-function deletion of exon 6 of the NIS gene was identified in a single case of follicular thyroid adenoma (Liang et al., 2005). Hyperfunctioning toxic adenomas harbor activating mutations of the TSH receptor and are characterized by increased NIS expression with correct plasma membrane localization (Lazar et al., 1999). |
| |
| |
Entity | Congenital Hypothyroidism |
Disease | Germinal NIS mutations causing iodide transport defect (ITD) are a rare cause of dyshormogenic congenital hypothyroidism (OMIM 274400). To date, 12 mutations have been reported (V59E, G93R, R124H, ΔM143-Q323, Q267E, C272X, T354P, G395R, ΔA439-P443, frame-shift 515X, Y531X, G543E) leading to reduced or absent thyroidal radioiodine uptake, low iodide saliva: plasma ratios and a variable degree of hypothyroidism and goiter. |
Prognosis | Goitre, severe neuro-developmental impairment and infertility if not treated. Hypothyroidism treated with T4-replacement therapy and I- supplementation. |
| |
Expression of the Na+/I- symporter (NIS) is markedly decreased or absent in gastric cancer and intestinal metaplastic mucosa of Barrett esophagus. |
Altorjay A, Dohan O, Szilagyi A, Paroder M, Wapnir IL, Carrasco N. |
BMC Cancer. 2007 Jan 10;7:5. |
PMID 17214887 |
|
Iodide symporter gene expression in human thyroid tumors. |
Arturi F, Russo D, Schlumberger M, du Villard JA, Caillou B, Vigneri P, Wicker R, Chiefari E, Suarez HG, Filetti S. |
J Clin Endocrinol Metab. 1998 Jul;83(7):2493-6. |
PMID 9661633 |
|
Cloning of a functional promoter of the human sodium/iodide-symporter gene. |
Behr M, Schmitt TL, Espinoza CR, Loos U. |
Biochem J. 1998 Apr 15;331 ( Pt 2):359-63. |
PMID 9531470 |
|
Do cell surface trafficking impairments account for variable cell surface sodium iodide symporter levels in breast cancer? |
Beyer SJ, Jimenez RE, Shapiro CL, Cho JY, Jhiang SM. |
Breast Cancer Res Treat. 2009 May;115(1):205-12. |
PMID 18500672 |
|
PTTG and PBF repress the human sodium iodide symporter. |
Boelaert K, Smith VE, Stratford AL, Kogai T, Tannahill LA, Watkinson JC, Eggo MC, Franklyn JA, McCabe CJ. |
Oncogene. 2007 Jun 28;26(30):4344-56. |
PMID 17297475 |
|
Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake. |
Castro MR, Bergert ER, Goellner JR, Hay ID, Morris JC. |
J Clin Endocrinol Metab. 2001 Nov;86(11):5627-32. |
PMID 11701745 |
|
Early cellular abnormalities induced by RET/PTC1 oncogene in thyroid-targeted transgenic mice. |
Cho JY, Sagartz JE, Capen CC, Mazzaferri EL, Jhiang SM. |
Oncogene. 1999 Jun 17;18(24):3659-65. |
PMID 10380889 |
|
Cloning and characterization of the thyroid iodide transporter. |
Dai G, Levy O, Carrasco N. |
Nature. 1996 Feb 1;379(6564):458-60. |
PMID 8559252 |
|
Predominant intracellular overexpression of the Na+/I- symporter (NIS) in a large sampling of thyroid cancer cases. |
Dohan O, Baloch Z, Banrevi Z, Livolsi V, Carrasco N. |
J Clin Endocrinol Metab. 2001 Jun;86(6):2697-700. |
PMID 11397873 |
|
The sodium/iodide Symporter (NIS): characterization, regulation and medical significance. |
Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, Ginter CS, Carrasco N. |
Endocr Rev. 2003 Feb;24(1):48-77. (REVIEW) |
PMID 12588808 |
|
BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. |
Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S, Russo D. |
J Clin Endocrinol Metab. 2007 Jul;92(7):2840-3. |
PMID 17488796 |
|
A preclinical large animal model of adenovirus-mediated expression of the sodium-iodide symporter for radioiodide imaging and therapy of locally recurrent prostate cancer. |
Dwyer RM, Schatz SM, Bergert ER, Myers RM, Harvey ME, Classic KL, Blanco MC, Frisk CS, Marler RJ, Davis BJ, O'Connor MK, Russell SJ, Morris JC. |
Mol Ther. 2005 Nov;12(5):835-41. |
PMID 16054438 |
|
Immunohistochemical expression of the human sodium/iodide symporter distinguishes malignant from benign gastric lesions. |
Farnedi A, Eusebi LH, Poli F, Foschini MP. |
Int J Surg Pathol. 2009 Aug;17(4):327-34. |
PMID 19124451 |
|
Identification of cyclic adenosine 3',5'-monophosphate response element modulator as an activator of the human sodium/iodide symporter upstream enhancer. |
Fenton MS, Marion KM, Hershman JM. |
Endocrinology. 2008 May;149(5):2592-606. |
PMID 18202121 |
|
Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells. |
Fortunati N, Catalano MG, Arena K, Brignardello E, Piovesan A, Boccuzzi G. |
J Clin Endocrinol Metab. 2004 Feb;89(2):1006-9. |
PMID 14764827 |
|
RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. |
Knauf JA, Kuroda H, Basu S, Fagin JA. |
Oncogene. 2003 Jul 10;22(28):4406-12. |
PMID 12853977 |
|
Differential regulation of the human sodium/iodide symporter gene promoter in papillary thyroid carcinoma cell lines and normal thyroid cells. |
Kogai T, Hershman JM, Motomura K, Endo T, Onaya T, Brent GA. |
Endocrinology. 2001 Aug;142(8):3369-79. |
PMID 11459780 |
|
Reverse transcriptase inhibitors down-regulate cell proliferation in vitro and in vivo and restore thyrotropin signaling and iodine uptake in human thyroid anaplastic carcinoma. |
Landriscina M, Fabiano A, Altamura S, Bagala C, Piscazzi A, Cassano A, Spadafora C, Giorgino F, Barone C, Cignarelli M. |
J Clin Endocrinol Metab. 2005 Oct;90(10):5663-71. |
PMID 16030158 |
|
Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. |
Lazar V, Bidart JM, Caillou B, Mahe C, Lacroix L, Filetti S, Schlumberger M. |
J Clin Endocrinol Metab. 1999 Sep;84(9):3228-34. |
PMID 10487692 |
|
A novel loss-of-function deletion in sodium/iodide symporter gene in follicular thyroid adenoma. |
Liang JA, Chen CP, Huang SJ, Ho TY, Hsiang CY, Ding HJ, Wu SL. |
Cancer Lett. 2005 Dec 8;230(1):65-71. |
PMID 16253762 |
|
Sodium iodide symporter is expressed at the preneoplastic stages of liver carcinogenesis and in human cholangiocarcinoma. |
Liu B, Herve J, Bioulac-Sage P, Valogne Y, Roux J, Yilmaz F, Boisgard R, Guettier C, Cales P, Tavitian B, Samuel D, Clerc J, Brechot C, Faivre J. |
Gastroenterology. 2007 Apr;132(4):1495-503. |
PMID 17408651 |
|
Expression of cAMP response element-binding protein and sodium iodide symporter in benign non-functioning and malignant thyroid tumours. |
Luciani P, Buci L, Conforti B, Tonacchera M, Agretti P, Elisei R, Vivaldi A, Cioppi F, Biliotti G, Manca G, Vitti P, Serio M, Peri A. |
Eur J Endocrinol. 2003 May;148(5):579-86. |
PMID 12720543 |
|
Correlation between 99mTc-pertechnetate uptakes and expressions of human sodium iodide symporter gene in breast tumor tissues. |
Moon DH, Lee SJ, Park KY, Park KK, Ahn SH, Pai MS, Chang H, Lee HK, Ahn IM. |
Nucl Med Biol. 2001 Oct;28(7):829-34. |
PMID 11578905 |
|
The paired-domain transcription factor Pax8 binds to the upstream enhancer of the rat sodium/iodide symporter gene and participates in both thyroid-specific and cyclic-AMP-dependent transcription. |
Ohno M, Zannini M, Levy O, Carrasco N, di Lauro R. |
Mol Cell Biol. 1999 Mar;19(3):2051-60. |
PMID 10022892 |
|
Immunoanalysis indicates that the sodium iodide symporter is not overexpressed in intracellular compartments in thyroid and breast cancers. |
Peyrottes I, Navarro V, Ondo-Mendez A, Marcellin D, Bellanger L, Marsault R, Lindenthal S, Ettore F, Darcourt J, Pourcher T. |
Eur J Endocrinol. 2009 Feb;160(2):215-25. |
PMID 19029227 |
|
Breast cancer brain metastases express the sodium iodide symporter. |
Renier C, Vogel H, Offor O, Yao C, Wapnir I. |
J Neurooncol. 2009 Jul 19. |
PMID 19618116 |
|
Endogenous NIS expression in triple-negative breast cancers. |
Renier C, Yao C, Goris M, Ghosh M, Katznelson L, Nowles K, Gambhir SS, Wapnir I. |
Ann Surg Oncol. 2009 Apr;16(4):962-8. |
PMID 19184238 |
|
A perspective view of sodium iodide symporter research and its clinical implications. |
Riesco-Eizaguirre G, Santisteban P. |
Eur J Endocrinol. 2006 Oct;155(4):495-512. (REVIEW) |
PMID 16990649 |
|
BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. |
Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V, Basolo F, Miccoli P, Pacini F, Pinchera A, Elisei R. |
Endocr Relat Cancer. 2008 Jun;15(2):511-20. |
PMID 18509003 |
|
Promoter characterization of the human Na+/I- symporter. |
Ryu KY, Tong Q, Jhiang SM. |
J Clin Endocrinol Metab. 1998 Sep;83(9):3247-51. |
PMID 9745437 |
|
Prognostic significance of human pituitary tumor-transforming gene immunohistochemical expression in differentiated thyroid cancer. |
Saez C, Martinez-Brocca MA, Castilla C, Soto A, Navarro E, Tortolero M, Pintor-Toro JA, Japon MA. |
J Clin Endocrinol Metab. 2006 Apr;91(4):1404-9. Epub 2006 Jan 17. |
PMID 16418208 |
|
Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas. |
Saito T, Endo T, Kawaguchi A, Ikeda M, Katoh R, Kawaoi A, Muramatsu A, Onaya T. |
J Clin Invest. 1998 Apr 1;101(7):1296-300. |
PMID 9525971 |
|
Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. |
Schmutzler C, Winzer R, Meissner-Weigl J, Kohrle J. |
Biochem Biophys Res Commun. 1997 Nov 26;240(3):832-8. |
PMID 9398654 |
|
Cloning of the human sodium lodide symporter. |
Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL, Jhiang SM. |
Biochem Biophys Res Commun. 1996 Sep 13;226(2):339-45. |
PMID 8806637 |
|
Expression, exon-intron organization and chromosome mapping of the human sodium iodide symporter. |
Smanik PA, Ryu KY, Theil KS, Mazzaferri EL, Jhiang SM. |
Endocrinology. 1997 Aug;138(8):3555-8. |
PMID 9231811 |
|
The sodium iodide symporter: its pathophysiological and therapeutic implications. |
Spitzweg C, Morris JC. |
Clin Endocrinol (Oxf). 2002 Nov;57(5):559-74. (REVIEW) |
PMID 12390328 |
|
A thyroid-specific far-upstream enhancer in the human sodium/iodide symporter gene requires Pax-8 binding and cyclic adenosine 3',5'-monophosphate response element-like sequence binding proteins for full activity and is differentially regulated in normal and thyroid cancer cells. |
Taki K, Kogai T, Kanamoto Y, Hershman JM, Brent GA. |
Mol Endocrinol. 2002 Oct;16(10):2266-82. |
PMID 12351692 |
|
The mammary gland iodide transporter is expressed during lactation and in breast cancer. |
Tazebay UH, Wapnir IL, Levy O, Dohan O, Zuckier LS, Zhao QH, Deng HF, Amenta PS, Fineberg S, Pestell RG, Carrasco N. |
Nat Med. 2000 Aug;6(8):871-8. |
PMID 10932223 |
|
Benign nonfunctioning thyroid adenomas are characterized by a defective targeting to cell membrane or a reduced expression of the sodium iodide symporter protein. |
Tonacchera M, Viacava P, Agretti P, de Marco G, Perri A, di Cosmo C, de Servi M, Miccoli P, Lippi F, Naccarato AG, Pinchera A, Chiovato L, Vitti P. |
J Clin Endocrinol Metab. 2002 Jan;87(1):352-7. |
PMID 11788674 |
|
Evidence for transcriptional and posttranscriptional alterations of the sodium/iodide symporter expression in hypofunctioning benign and malignant thyroid tumors. |
Trouttet-Masson S, Selmi-Ruby S, Bernier-Valentin F, Porra V, Berger-Dutrieux N, Decaussin M, Peix JL, Perrin A, Bournaud C, Orgiazzi J, Borson-Chazot F, Franc B, Rousset B. |
Am J Pathol. 2004 Jul;165(1):25-34. |
PMID 15215159 |
|
Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status. |
Venkataraman GM, Yatin M, Marcinek R, Ain KB. |
J Clin Endocrinol Metab. 1999 Jul;84(7):2449-57. |
PMID 10404820 |
|
The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid. |
Wapnir IL, Goris M, Yudd A, Dohan O, Adelman D, Nowels K, Carrasco N. |
Clin Cancer Res. 2004 Jul 1;10(13):4294-302. |
PMID 15240514 |
|
Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast and other carcinomas using high density tissue microarrays and conventional sections. |
Wapnir IL, van de Rijn M, Nowels K, Amenta PS, Walton K, Montgomery K, Greco RS, Dohan O, Carrasco N. |
J Clin Endocrinol Metab. 2003 Apr;88(4):1880-8. |
PMID 12679487 |
|
Low expression of sodium iodide symporter identifies aggressive thyroid tumors. |
Ward LS, Santarosa PL, Granja F, da Assumpcao LV, Savoldi M, Goldman GH. |
Cancer Lett. 2003 Oct 8;200(1):85-91. |
PMID 14550956 |
|
Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. |
Zarnegar R, Brunaud L, Kanauchi H, Wong M, Fung M, Ginzinger D, Duh QY, Clark OH. |
Surgery. 2002 Dec;132(6):984-90. |
PMID 12490845 |
|